Foghorn Therapeutics Inc. (FHTX) Revenue by Segment & Business Profile
Oncology drug candidates for cancer patients was 100.0% of Foghorn Therapeutics Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FHTXFoghorn Therapeutics Inc.Follow FHTX — free
—
Price chart with a free account
- Market cap
- 118.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What the company does
Foghorn Therapeutics Inc. is a drug manufacturers - general company in the healthcare sector. Trailing twelve-month revenue: $36.7 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Large-cap pharmaceuticals
Foghorn Therapeutics Inc. — questions
- What does Foghorn Therapeutics Inc. do?
- Foghorn Therapeutics Inc. is a drug manufacturers - general company in the healthcare sector. Trailing twelve-month revenue: $36.7 million as of 2026-06-30.
- How does Foghorn Therapeutics Inc. make money?
- By the lines it reports in its SEC filings: Oncology drug candidates for cancer patients 100.0% of revenue.
Every figure on this page comes from Foghorn Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.